Baidu
map

王燕教授:纵览EGFR突变阳性晚期NSCLC治疗,优化患者管理

2020-04-14 佚名 肿瘤资讯

EGFR突变是中国晚期非小细胞肺癌(NSCLC)患者最常见的驱动基因,其包括19外显子缺失突变(19del)和21外显子L858R点突变(21L858R)等常见突变,也包括20外显子插入突变等罕见突变

EGFR突变是中国晚期非小细胞肺癌(NSCLC)患者最常见的驱动基因,其包括19外显子缺失突变(19del)和21外显子L858R点突变(21L858R)等常见突变,也包括20外显子插入突变等罕见突变。随着研究证据的积累,我们发现,不同突变类型患者接受EGFR TKI治疗的疗效以及患者的预后有所差异,需要区别对待。

精准治疗时代,EGFR 19del、21L858R突变和少见突变NSCLC患者需要区分对待

对于EGFR突变阳性晚期NSCLC患者,目前的治疗方式非常丰富,包括3个一代,2个二代以及2个三代EGFR TKI药物。对于这部分患者,如何选择一线治疗,如何进行全程管理,是大家非常关注的问题。越来越多的数据表明,EGFR不同突变类型的患者,其对不同药物的疗效以及预后不尽相同,需要区别对待。这些不同的突变,对药物的敏感性不同,对其进行区别,有助于指导患者的后续治疗和管理。对于19del和L858R突变患者来说,一、二、三代EGFR TKI治疗都是敏感的,但随着我们对疗效的预期越来越高,我们发现19del和21L858R对EGFR TKI的疗效存在一些差异,这两类患者的预后也有所不同。疗效的差异更多的是源于突变本身的性质,即不同突变位点的EGFR激酶功能区域不同。所以现在,我们更倾向于将19del和21L858R作为两种不同的疾病亚型来管理。从近期比较关注的几个临床研究来看,包括FLAURA研究(奥希替尼 vs 吉非替尼/厄洛替尼)、ARCHER 1050研究(达可替尼 vs 吉非替尼)、CTONG 1509研究(贝伐珠单抗联合厄洛替尼,即A+T方案 vs 厄洛替尼单药),以及INCREASE研究(埃克替尼加倍剂量 vs 常规剂量治疗21L858R),这些研究数据告诉我们19del和 21L858R突变患者应该区别对待,并就治疗方案为我们提供了一些参考。

对于19del患者,在既往评估第一或第二代EGFR TKI单药治疗疗效的研究中,19del的获益都较好,在此基础之上,三代TKI的疗效更上一层楼,相比一代TKI延长了患者总体生存。基于FLAURA研究的结果,临床逐渐尝试奥希替尼一线治疗的模式。但在亚洲人群和21L858R突变亚组中,目前的TKI单药还没有能够为L858R提供解决方案。这就引起了我们对于21L858R突变患者更多的关注,探索是否存在更好的治疗策略。

而刚刚提到的其他三项研究数据,可以给我们一些补充。在CTONG 1509研究中,A+T方案对比厄洛替尼单药具有显着的无进展生存(PFS)优势,达到18.0个月,降低疾病进展风险45%,特别对于L858R突变的患者,A+T模式扭转了既往单药治疗的劣势,同时不良反应可控可管理。在ARCHER 1050研究中,对于21L858R患者,达可替尼相比吉非替尼具有一定优势。在INCREASE研究中,专门针对21L858R突变,埃克替尼加量对比常规剂量有PFS优势。因此,对于21L858R突变患者而言,虽然FLAURA研究并没有观察到奥希替尼明显的优势,但A+T方案,达可替尼和埃克替尼加量这三种方式似乎都是可选的治疗策略。在这三种治疗方式中,A+T方案的PFS最长,达到了19.5个月,是目前针对L858R人群中PFS最长的治疗方案。总生存时间(OS)方面,ARCHER 1050研究中OS没有获益,而CTONG 1509研究尚未公布OS结果,期待后续随访数据。而INCREASE研究是一项Ⅱ期临床研究,期待后续Ⅲ期临床研究的验证。

对于少见突变患者,目前数据比较多的是阿法替尼,如S768I、G719X、L861Q等少见突变,都对阿法替尼相对敏感。2019年发表的一项研究数据显示,奥希替尼对这些少见突变也有一定疗效。在众多的少见突变中,20外显子插入突变的治疗比较困难,其对一、二、三代EGFR TKI治疗的效果都不太好,目前针对20外显子插入突变患者,已经开展了一些新药研究。在今后的EGFR突变阳性晚期NSCLC患者管理中,我们需要进一步优化检测方法,除了检测常见突变,还应该覆盖更广,检测是否存在少见突变和共存突变,因为有研究发现,一些共存突变也会影响患者接受EGFR TKI治疗的疗效。

总体而言,关于EGFR突变阳性晚期NSCLC患者的最佳治疗选择,目前并没有唯一的答案。在具体制定方案时,需要考虑患者的治疗意愿以及治疗期待,兼顾基础疾病后进行综合考虑。同时,还要考虑当地的医保政策。目前,可供选择的药物越来越多,研究数据也层出不穷,为治疗决策提供基础的同时,也要求治疗方案更为细化。

A+T在21L858R突变NSCLC患者中取得目前最长无进展生存,未来可期

对于EGFR突变阳性晚期NSCLC患者,我们确实看到不同突变位点的患者对药物的疗效不同,这就激发我们对治疗效果欠佳的21L858R突变亚组,进行更多的探索。

目前而言,A+T模式在21L858R突变患者中可以取得最好的PFS。对于这类共存突变发生率更高、使用EGFR TKI单药效果不好的患者,联合治疗可能是更好的模式。联合模式除了A+T模式以外,也可以联合其他药物,比如EGFR TKI联合化疗或其他,这是我们探索的方向。需要指出的是,当EGFR TKI和化疗联合时,不良反应会增加,多数人由于惧怕化疗,可能会影响治疗的进行,并最终影响疗效。与之相比,A+T模式更符合患者的心理预期。就经济花费上而言,A+T方案中的两个药物都已经纳入医保,患者无需过于担心。虽然两药联用可能会增加不良反应,影响患者的耐受性,但从目前的数据来看,对于L858R突变患者选择A+T联合治疗,耐受性尚可,总体不良反应可控。

未来,我们还有非常多的探索空间。第一,我们在CTONG 1509研究中已经看到了A+T的PFS优势,其OS是否也有优势?我们期待后续更长时间的随访报道。第二,患者使用A+T的耐药机制,是否和既往厄洛替尼单药的耐药机制相同呢?目前认为,患者后续仍以T790M耐药突变为主,肿瘤在经过治疗后可能表现出更多的均一性,更有利于后续的耐药后治疗。这也需要后续更多的研究来验证。另外,在一些EGFR少见突变方面,是否也可以进行A+T治疗模式的探索。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1803602, encodeId=d0031803602da, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75520, encryptionId=dcdce5520b4, topicName=突变阳性晚期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Jun 06 03:12:22 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803557, encodeId=1923180355e12, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Tue Aug 25 03:12:22 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785101, encodeId=f0141e8510166, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue May 12 10:12:22 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416326, encodeId=410d14163265b, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534491, encodeId=561815344916a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546037, encodeId=ddb6154603ee6, content=<a href='/topic/show?id=3e0453069aa' target=_blank style='color:#2F92EE;'>#患者管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53069, encryptionId=3e0453069aa, topicName=患者管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=179213855182, createdName=ms7421025882867189, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039756, encodeId=ba281039e56a6, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue Apr 14 18:12:22 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1803602, encodeId=d0031803602da, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75520, encryptionId=dcdce5520b4, topicName=突变阳性晚期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Jun 06 03:12:22 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803557, encodeId=1923180355e12, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Tue Aug 25 03:12:22 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785101, encodeId=f0141e8510166, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue May 12 10:12:22 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416326, encodeId=410d14163265b, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534491, encodeId=561815344916a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546037, encodeId=ddb6154603ee6, content=<a href='/topic/show?id=3e0453069aa' target=_blank style='color:#2F92EE;'>#患者管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53069, encryptionId=3e0453069aa, topicName=患者管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=179213855182, createdName=ms7421025882867189, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039756, encodeId=ba281039e56a6, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue Apr 14 18:12:22 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1803602, encodeId=d0031803602da, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75520, encryptionId=dcdce5520b4, topicName=突变阳性晚期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Jun 06 03:12:22 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803557, encodeId=1923180355e12, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Tue Aug 25 03:12:22 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785101, encodeId=f0141e8510166, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue May 12 10:12:22 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416326, encodeId=410d14163265b, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534491, encodeId=561815344916a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546037, encodeId=ddb6154603ee6, content=<a href='/topic/show?id=3e0453069aa' target=_blank style='color:#2F92EE;'>#患者管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53069, encryptionId=3e0453069aa, topicName=患者管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=179213855182, createdName=ms7421025882867189, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039756, encodeId=ba281039e56a6, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue Apr 14 18:12:22 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1803602, encodeId=d0031803602da, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75520, encryptionId=dcdce5520b4, topicName=突变阳性晚期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Jun 06 03:12:22 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803557, encodeId=1923180355e12, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Tue Aug 25 03:12:22 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785101, encodeId=f0141e8510166, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue May 12 10:12:22 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416326, encodeId=410d14163265b, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534491, encodeId=561815344916a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546037, encodeId=ddb6154603ee6, content=<a href='/topic/show?id=3e0453069aa' target=_blank style='color:#2F92EE;'>#患者管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53069, encryptionId=3e0453069aa, topicName=患者管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=179213855182, createdName=ms7421025882867189, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039756, encodeId=ba281039e56a6, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue Apr 14 18:12:22 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1803602, encodeId=d0031803602da, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75520, encryptionId=dcdce5520b4, topicName=突变阳性晚期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Jun 06 03:12:22 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803557, encodeId=1923180355e12, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Tue Aug 25 03:12:22 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785101, encodeId=f0141e8510166, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue May 12 10:12:22 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416326, encodeId=410d14163265b, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534491, encodeId=561815344916a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546037, encodeId=ddb6154603ee6, content=<a href='/topic/show?id=3e0453069aa' target=_blank style='color:#2F92EE;'>#患者管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53069, encryptionId=3e0453069aa, topicName=患者管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=179213855182, createdName=ms7421025882867189, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039756, encodeId=ba281039e56a6, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue Apr 14 18:12:22 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2020-04-16 liuyiping
  6. [GetPortalCommentsPageByObjectIdResponse(id=1803602, encodeId=d0031803602da, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75520, encryptionId=dcdce5520b4, topicName=突变阳性晚期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Jun 06 03:12:22 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803557, encodeId=1923180355e12, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Tue Aug 25 03:12:22 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785101, encodeId=f0141e8510166, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue May 12 10:12:22 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416326, encodeId=410d14163265b, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534491, encodeId=561815344916a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546037, encodeId=ddb6154603ee6, content=<a href='/topic/show?id=3e0453069aa' target=_blank style='color:#2F92EE;'>#患者管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53069, encryptionId=3e0453069aa, topicName=患者管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=179213855182, createdName=ms7421025882867189, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039756, encodeId=ba281039e56a6, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue Apr 14 18:12:22 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1803602, encodeId=d0031803602da, content=<a href='/topic/show?id=dcdce5520b4' target=_blank style='color:#2F92EE;'>#突变阳性晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75520, encryptionId=dcdce5520b4, topicName=突变阳性晚期)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Jun 06 03:12:22 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803557, encodeId=1923180355e12, content=<a href='/topic/show?id=0b3fe551971' target=_blank style='color:#2F92EE;'>#突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75519, encryptionId=0b3fe551971, topicName=突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Tue Aug 25 03:12:22 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785101, encodeId=f0141e8510166, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6599, encryptionId=0b4f65992c, topicName=EGFR突变阳性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Tue May 12 10:12:22 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416326, encodeId=410d14163265b, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534491, encodeId=561815344916a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546037, encodeId=ddb6154603ee6, content=<a href='/topic/show?id=3e0453069aa' target=_blank style='color:#2F92EE;'>#患者管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53069, encryptionId=3e0453069aa, topicName=患者管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=179213855182, createdName=ms7421025882867189, createdTime=Thu Apr 16 06:12:22 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039756, encodeId=ba281039e56a6, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Tue Apr 14 18:12:22 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2020-04-14 肿肿

    NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了

    0

相关资讯

JCO:不建议厄洛替尼联合贝伐单抗用于晚期NSCLC维持治疗

研究要点:1.既往研究表明,厄洛替尼联合贝伐单抗策略具有较好的耐受性及抗肿瘤活性;本研究旨在评价含贝伐单抗一线化疗后,厄洛替尼联合贝伐单抗维持治疗晚期NSCLC的潜在获益情况。2.研究表明,厄洛替尼联合贝伐单抗方案可显著改善患者PFS,但不能显著改善患者OS。3.总体而言,患者耐受性良好;维持治疗方案对生存结局影响较小,且毒性增加。在2013年10月7日在线出版的《临床肿瘤学杂志》(Journ

JAMA Oncol:延期的非小细胞肺癌的术后辅助化疗依然有效

肺癌是一种发病率较高的恶性肿瘤,手术是唯一能够治愈的治疗办法,但是即使手术后,肺癌的长期生存率也不理想。因此,对于可手术切除的早中期(I-IIIA)非小细胞肺癌(NSCLC)的治疗,有了术后辅助治疗和术前新辅助治疗。术前新辅助治疗目的为抑制肿瘤原发病灶,杀灭可能存在的微小转移灶,降低术中肿瘤生长因子的释放。术后辅助治疗的原理为根治术后的NSCLC患者可能存在微小转移灶进而出现远处转移的风险,术后治

Lancet:Atezolizumab可显著提高非小细胞肺癌(NSCLC)患者的生存率

以前经过治疗的,晚期或转移性非小细胞肺癌(NSCLC)患者预后较差。抗程序性死亡配体1(PD-L1的)抗体atezolizumab针对癌症,包括NSCLC具有临床活性,特别是对于肿瘤细胞和肿瘤浸润免疫细胞表达PD-L1的癌症,或两者均表达的癌症。研究人员评估了多西紫杉醇和atezolizumab对于之前经过治疗的NSCLC的安全性和疗效,由PD-L1在肿瘤细胞和肿瘤浸润免疫细胞的表达水平进行分析,

拓展阅读

ESMO 2024 | 专访张洁教授:丙酸倍氯米松吸入剂在局部晚期NSCLC根治性放疗中的应用,降低放射性肺炎发生率的新策略

在2024年欧洲内科肿瘤学会(ESMO)年会上,来自上海市肺科医院的张洁教授展现了其创新研究成果。梅斯医学紧跟学术前沿,特邀张洁教授对这一重磅研究成果进行解读以及研究结果对现有治疗策略的影响。

ELCC 2024 :围手术期纳武利尤单抗与新辅助化疗+后续辅助纳武利尤单抗治疗可切除NSCLC患者的健康相关生活质量结果(CheckMate 77T研究)

与化疗/安慰剂相比,围手术期NIVO不会对治疗期间的HRQoL产生不利影响,并能降低病情恶化风险。

ELCC 2024 :外泌体生物标志物或可成为非小细胞肺癌(NSCLC)患者预后标志物

外泌体mRNA可作为一种可检测且易获得的生物标志物,为临床的治疗方案选择提供指导。Hippo和HIF1A通路可能在NSCLC中起关键作用,从而提供了潜在的治疗途径。

ELCC 2024:气腔内播散对接受肺叶切除术与肺段切除术治疗的I期NSCLC患者总生存期和无复发生存期的影响

对于伴有STAS的临床I期NSCLC患者,更容易表现为实性结节、脉管浸润、进展分期以及高度侵袭性的病理亚型。肺叶切除术的RFS和OS优于肺段切除术。

多中心研究:对奥希替尼获得性耐药的T790M突变NSCLC更有效

该研究表明,基于抗血管生成的治疗可能改善对奥希替尼获得性耐药的EGFR突变NSCLC患者的PFS和OS。此外,基于安罗替尼的治疗可能是此类患者的一种有前景的有效治疗方法。

2023 WCLC|转移性NSCLC免疫治疗

WCLC是致力于肺癌和其他胸部恶性肿瘤的多学科肿瘤学会议,来自全球100多个国家的7000多名专业人士参会,共同探讨肺癌和其他胸部恶性肿瘤的前沿诊疗进展。

Baidu
map
Baidu
map
Baidu
map